These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 16599651)

  • 1. Ziconotide.
    Lyseng-Williamson KA; Perry C
    CNS Drugs; 2006; 20(4):331-8; discussion 339-41. PubMed ID: 16599651
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intrathecal ziconotide in the treatment of refractory pain in patients with cancer or AIDS: a randomized controlled trial.
    Staats PS; Yearwood T; Charapata SG; Presley RW; Wallace MS; Byas-Smith M; Fisher R; Bryce DA; Mangieri EA; Luther RR; Mayo M; McGuire D; Ellis D
    JAMA; 2004 Jan; 291(1):63-70. PubMed ID: 14709577
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Ziconotide--a novel neuron-specific calcium channel blocker for the intrathecal treatment of severe chronic pain--a short review.
    Klotz U
    Int J Clin Pharmacol Ther; 2006 Oct; 44(10):478-83. PubMed ID: 17063978
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Intrathecal ziconotide for refractory pain.
    Doggrell SA
    Expert Opin Investig Drugs; 2004 Jul; 13(7):875-7. PubMed ID: 15212625
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of morphine in patients receiving ziconotide for severe chronic pain.
    Webster LR; Fakata KL; Charapata S; Fisher R; MineHart M
    Pain Med; 2008 Apr; 9(3):282-90. PubMed ID: 18366508
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Phase II, open-label, multicenter study of combined intrathecal morphine and ziconotide: addition of ziconotide in patients receiving intrathecal morphine for severe chronic pain.
    Wallace MS; Kosek PS; Staats P; Fisher R; Schultz DM; Leong M
    Pain Med; 2008 Apr; 9(3):271-81. PubMed ID: 18366507
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intrathecal combination of ziconotide and morphine for refractory cancer pain: a rapidly acting and effective choice.
    Alicino I; Giglio M; Manca F; Bruno F; Puntillo F
    Pain; 2012 Jan; 153(1):245-249. PubMed ID: 22082570
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ziconotide: new drug. Limited analgesic efficacy, too many adverse effects.
    Prescrire Int; 2008 Oct; 17(97):179-82. PubMed ID: 19530373
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intrathecal ziconotide and opioid combination therapy for noncancer pain: an observational study.
    Deer TR; Kim C; Bowman R; Tolentino D; Stewart C; Tolentino W
    Pain Physician; 2009; 12(4):E291-6. PubMed ID: 19668287
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Italian registry on long-term intrathecal ziconotide treatment.
    Raffaeli W; Sarti D; Demartini L; Sotgiu A; Bonezzi C;
    Pain Physician; 2011; 14(1):15-24. PubMed ID: 21267038
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Intrathecal ziconotide for refractory chronic pain.
    Lynch SS; Cheng CM; Yee JL
    Ann Pharmacother; 2006; 40(7-8):1293-300. PubMed ID: 16849624
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pharmacokinetics and pharmacodynamics of intrathecal ziconotide in chronic pain patients.
    Wermeling D; Drass M; Ellis D; Mayo M; McGuire D; O'Connell D; Hale V; Chao S
    J Clin Pharmacol; 2003 Jun; 43(6):624-36. PubMed ID: 12817525
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Intrathecal ziconotide: a review of its use in patients with chronic pain refractory to other systemic or intrathecal analgesics.
    Sanford M
    CNS Drugs; 2013 Nov; 27(11):989-1002. PubMed ID: 23999971
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ziconotide for treatment of severe chronic pain.
    Schmidtko A; Lötsch J; Freynhagen R; Geisslinger G
    Lancet; 2010 May; 375(9725):1569-77. PubMed ID: 20413151
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Ziconotide: can we use it in palliative care?
    Prommer EE
    Am J Hosp Palliat Care; 2005; 22(5):369-74. PubMed ID: 16225359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term intrathecal ziconotide for chronic pain: an open-label study.
    Webster LR; Fisher R; Charapata S; Wallace MS
    J Pain Symptom Manage; 2009 Mar; 37(3):363-72. PubMed ID: 18715748
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cost-effectiveness of ziconotide in intrathecal pain management for severe chronic pain patients in the UK.
    Dewilde S; Verdian L; Maclaine GD
    Curr Med Res Opin; 2009 Aug; 25(8):2007-19. PubMed ID: 19563256
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Intrathecal ziconotide for severe chronic pain: safety and tolerability results of an open-label, long-term trial.
    Wallace MS; Rauck R; Fisher R; Charapata SG; Ellis D; Dissanayake S;
    Anesth Analg; 2008 Feb; 106(2):628-37, table of contents. PubMed ID: 18227325
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Ziconotide adverse events in patients with cancer pain: a multicenter observational study of a slow titration, multidrug protocol.
    Dupoiron D; Bore F; Lefebvre-Kuntz D; Brenet O; Debourmont S; Dixmerias F; Buisset N; Lebrec N; Monnin D
    Pain Physician; 2012; 15(5):395-403. PubMed ID: 22996851
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Intrathecal ziconotide and baclofen provide pain relief in seven patients with neuropathic pain and spasticity: case reports.
    Saulino M; Burton AW; Danyo DA; Frost S; Glanzer J; Solanki DR
    Eur J Phys Rehabil Med; 2009 Mar; 45(1):61-7. PubMed ID: 19156022
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.